Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Cachofeiro, Victoria ^a,c   Goicochea, Marian ^b   De Vinuesa, Soledad García ^b   Oubĩa, Pilar ^a   Lahera, Vicente ^a   Lũo, José ^b  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Chronic kidney disease; Dyslipemia; Inflammation; Oxidative stress; Statin

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; CHRONIC DISEASE; DRUG EFFECT; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY DISEASES; OXIDATIVE STRESS; RISK FACTORS;

EID: 57049146797     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.516     Document Type: Conference Paper

References (54)

1. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18.
2. Fried LF, Shlipak MG, Crump C et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality an elderly individuals. J Am Coll Cardiol 2003; 41: 1364-1372.
3. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
4. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease. Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
5. Chobanian AV, Barkris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
6. Mitka M. Guidelines offer 'roadmap' for chronic kidney disease. JAMA 2002; 287: 973.
7. Diepeveen SH, Wetzels JF, Bilo HJ et al. Cholesterol in end-stage renal disease: the good, the bad or the ugly? Neth J Med 2008; 66: 53-61.
8. Heitzer T, Schlinzig T, Krohn K et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
10. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
11. Münzel T, Just H, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. In: Born GVR, Schwartz CJ (eds). Vascular Endothelium: Physiology, Pathology and Therapeutic Options. Schattauer: Stuttgart, 1997, pp 205-220.
12. Newby AC, Zaltsman AB. Fibrous cap formation or destruction: the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999; 41: 345-360.
13. Rodriguez JA, Orbe J, Paramo JA. Metalloproteases, vascular remodeling, and atherothrombotic syndromes. Rev Esp Cardiol 2007; 60: 959-967.
14. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83: 361-366.
15. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007; 83: 84-92.
16. Portaluppi F, Boari B, Manfredini R. Oxidative stress in essential hypertension. Curr Pharm Des 2004; 10: 1695-1698.
17. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999; 43: 521-531.
18. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 2003; 91: 179-194.
19. Dobashi K, Ghosh B, Orak JK et al. Kidney ischemia-reperfusion: modulation of antioxidant defenses. Mol Cell Biochem 2000; 205: 1-11.
20. Dounousi E, Papavasiliou E, Makedou A et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-760.
21. Karamouzis I, Sarafidis PA, Karamouzis M et al. Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 2008; 28: 397-404.
22. Ferretti G, Bacchetti T, Masciangelo S et al. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008; 41: 381-386.
23. Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in hemodyalisis patients: effect of dialysis and comparison with matched controls. Atherosclerosis 1997; 129: 199-205.
24. Terawaki K, Yoshimura K, Hasegawa T et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004; 66: 1989-1993.
25. Quiroz Y, Ferrebuz A, Romero F et al. Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 2008; 294: F336-F444.
26. Haffner SM. Clinical relevance of the oxidative stress concept. Metabolism 2000; 49(Suppl 1): 30-34.
27. Lahera V, Goicoechea M, de Vinuesa SG et al. Oxidative stress in uremia: the role of anemia correction. J Am Soc Nephrol 2006; 17(Suppl 3): S174-S177.
28. Fortuño A, Beloqui O, San José G et al. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. Kidney Int Suppl 2005; 99: S71-S75.
29. Castilla P, Dávalos A, Teruel JL et al. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr 2008; 87: 1053-1061.
30. Grahl DA, Axelsson J, Nordfors L et al. Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients. Blood Purif 2007; 25: 210-218.
31. Perianayagam MC, Liangos O, Kolyada AY et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18: 255-263.
32. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Malnutrition-inflammation score for risk stratification of patients with CKD: is it the promised gold standard? Nat Clin Pract Nephrol 2008; 4: 354-355.
33. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253.
34. García de Vinuesa MS, Goicoechea M, Kanter J et al. Insulin resistance, inflammatory biomarkers and adipokines in patients with chronic kidenay disease: efects of angiotensin II blockade. J Am Soc Nephrol 2006; 17(12 Suppl 3): S206-S212.
35. Goicoechea M, García de Vinuesa MS, Lahera V et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(12 Suppl 3): S231-S235.
36. Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther 2006; 2: 111-119.
37. Merino A, Nogueras S, Buendía P et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol 2008; 161: 83-88.
38. Sela S, Shurtz-Swirski R, Cohen-Mazor M et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2431-2438.
39. Fried L, Solomon C, Shlipak M et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15: 3184-3191.
40. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
41. Jabs WJ, Lögering BA, Gerke P et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 2003; 33: 152-161.
42. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117: 499-507.
43. Li N, Karin M. Is NF-κB the sensor of oxidative stress? FASEB J 1999; 13: 1137-1143.
44. Schreck R, Rieber P, Beauerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-2252.
45. Baber U, Toto RD, de Lemos JA. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J 2007; 153: 471-477.
46. Holdaas H, Fellström B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929-2936.
47. Wanner C, Krane V. Lessons learnt from the 4D trial. Nephrol Ther 2006; 2: 3-7.
48. Zhou MS, Schulman IH, Jaimes EA et al. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGFβ and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295: F53-F59.
49. Panichi V, Paoletti S, Mantuano E et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006; 21: 337-344.
50. Di Renzo L, Noce A, De Angelis S et al. Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. Pharmacol Res 2008; 57: 93-99.
51. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
52. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007; 49: 2003-2009.
53. Alvarez-Sala LA, Cachofeiro V, Masana L et al. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther 2008; 30: 84-97.
54. Mastalerz-Migas A, Reksa D, Pokorski M et al. Comparison of a statin vs hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 2007; 58(Suppl 5, Part 1): 363-370.